When Maria Rodriguez, a 72-year-old retiree from Nashville, went in for cataract surgery last year, she didn’t expect it would also free her from the daily ritual of glaucoma eye drops she’d struggled with for nearly a decade. But thanks to an experimental new lens, that’s exactly what happened. The artificial lens implanted during her routine surgery slowly releases medication to control eye pressure, treating both cataracts and glaucoma in one procedure. For millions facing both conditions, this could be life-changing.
Glaucoma, a leading cause of irreversible blindness, damages the optic nerve when pressure builds up inside the eye. The standard treatment—daily eye drops—works, but only if people use them consistently. Many don’t. Drops can be hard to administer, especially for older adults with shaky hands or poor vision. Missed doses mean rising pressure and greater risk of vision loss. Cataracts, which cloud the eye’s natural lens, are also common in older adults and often require surgery. Researchers saw a rare opportunity: what if that same surgery could also solve the problem of daily drops?
At Vanderbilt University Medical Center, Dr. Jeffrey Kammer and his team tested a new lens embedded with tiny reservoirs of bimatoprost, a widely used glaucoma drug. In a clinical trial of 106 patients, three-quarters received the drug-releasing lens—either a high or low dose—while the rest got a standard lens and used twice-daily timolol eye drops. After one year, eye pressure dropped to 15.9 mmHg in the high-dose group, 14.8 mmHg in the low-dose group, and 15.7 mmHg in the control group—nearly identical results, but with a crucial difference. More than 95% of patients with the experimental lens no longer needed any glaucoma medication.
That means one surgery, one recovery, and two diseases managed at once. "Imagine being able to treat two of the most common eye diseases, cataract and glaucoma, in one sitting," Dr. Kammer said. "There is simply nothing like it in development."
The implications are profound. With over 80 million people worldwide living with glaucoma—and cataract surgery performed millions of times each year—this lens could simplify treatment on a massive scale. Patients would no longer rely on memory, coordination, or access to daily medication. The trial participants will be followed for three years, and two larger studies are already underway to confirm long-term safety and effectiveness.
For people like Maria, who now sees clearly without the burden of drops, the future feels brighter. As researchers continue to refine this innovation, the dream of easier, more reliable eye care is coming into focus—one lens at a time.